Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers
In a linked Surveillance, Epidemiology, and End Results and Medicare study reported in the Journal of Clinical Oncology, Salz et al found...
Activity of Cabozantinib in Advanced Non–Clear Cell Renal Cell Carcinoma
In a retrospective cohort study reported in The Lancet Oncology, Chanzá et al found evidence of activity of cabozantinib in advanced non–clear cell renal carcinoma...
Addition of Pegylated Recombinant Human Hyaluronidase to FOLFIRINOX in Metastatic Pancreatic Adenocarcinoma
In the phase I/II SWOG S1313 trial, which was reported in the Journal of Clinical Oncology by Ramanathan et al, researchers found that the addition of...
Pembrolizumab/Axitinib Combination Improves Outcomes vs Sunitinib in Kidney Cancer
The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved...
Mutations in DNA Damage Repair Predict Benefit With Platinum Agents in Pancreatic Cancer
Patients with advanced pancreatic cancer who have homologous repair damage response mutations may derive considerable benefit from treatment with platinum agents...
Gordon Schiff and colleagues: Patient-Centered Principles for Cancer Diagnosis
Shaji Kumar: Reshaping the Treatment Landscape in Refractory Multiple Myeloma
Thaddeus Mason Pope: Health-Care Fraud Prosecutions
Cardinale Smith: Improving Education on the Tenets of Palliative Care
Derek Raghvan: 'Curve 2' and Oncology
More Top Stories
Roy L. Silverstein, MD, Begins Term as 2019 ASH President
ROY L. SILVERSTEIN, MD, an expert in platelet and vascular cell biology, as well as clinical nonmalignant hematology and thrombosis, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2019. Dr. Silverstein is Chairman of the Department of...
FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer
On March 18, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer. IMpower133 Approval was based on the IMpower133 study, a...
ARAMIS Trial Reports Darolutamide Improves Outcomes in High-Risk Nonmetastatic Prostate Cancer
Darolutamide—an investigational androgen receptor inhibitor—significantly improved metastasis-free survival in men with high-risk nonmetastatic castration-resistant prostate cancer vs placebo in the large phase III ARAMIS trial.1 Men treated with darolutamide had a median metastasis-free survival...
Humanitarian, Cancer Specialist Advocates for Universal Access to Care as a Basic Human Right
There is a plethora of educational books for patients with cancer and their families; advocates and patients themselves write most. Books in this genre often have a difficult time distilling the hard science of oncology into a lay-friendly narrative that keeps the reader engaged from cover to...
EAU 2019: Testosterone Replacement Therapy May Slow Recurrence in Low-Risk Prostate Cancer
Researchers have shown that testosterone replacement may slow the recurrence of prostate cancer in low-risk patients. Findings from the study were presented by Towe et al at the European Association of Urology (EAU) 2019 Congress (Abstract 646). Practitioners have long regarded testosterone as a...
Roy L. Silverstein, MD, Begins Term as 2019 ASH President
ROY L. SILVERSTEIN, MD, an expert in platelet and vascular cell biology, as well as clinical nonmalignant hematology and thrombosis, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2019. Dr. Silverstein is Chairman of the Department of...
EAU 2019: Early Menopause in Smokers May Be Linked to Increased Risk of Bladder Cancer
New research has shown that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer; this higher risk was even more notable in smokers. The study, which looked at health outcomes in more than 220,000 patients, was presented by Abufaraj et al at the European...
Nicholas Vogelzang, MD, on Urothelial Cancer: Results From a Trial on Lenvatinib Plus Pembrolizumab
Toni K. Choueiri, MD, and Ziad Bakouny, MD, on Renal Cell Carcinoma: Next-Generation Immuno-oncology Therapies
Michael Gnant, MD, on Breast Cancer: Results From the ABCSG-18 Trial
Sagar Lonial, MD, on Multiple Myeloma: Sequencing Therapies
